Fasting blood glucose and lipid profile alterations following twelve-month androgen deprivation therapy in men with prostate cancer

The Scientific World Journal

Volumn 2012, Issue , 2012, Pages

  Saǧlam, Hasan S ^a   Köse, Osman ^a   Kumsar, Şükrü ^a   Budak, Salih ^a   Adsan, Öztuǧ ^a  

^a SAKARYA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; GOSERELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEUPRORELIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANDROGEN; ANTIANDROGEN; CHOLESTEROL; LIPID;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANTIANDROGEN THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HUMAN; MALE; ORCHIECTOMY; PROSTATE CANCER; RETROSPECTIVE STUDY; BLOOD; DIET RESTRICTION; DRUG EFFECT; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROGENS; BLOOD GLUCOSE; CHOLESTEROL; FASTING; HUMANS; LIPIDS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84876025925     PISSN: 1537744X     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/2012/696329     Document Type: Article

References (20)

1. Meng M. V., Grossfeld G. D., Sadetsky N., Mehta S. S., Lubeck D. P., Carroll P. R., Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 2002 60 3, supplement 1 7 11 2-s2.0-18644367900 10.1016/S0090-4295(02)01560-1 (Pubitemid 35304536)
2. Loblaw D. A., Virgo K. S., Nam R., Somerfield M. R., Ben-Josef E., Mendelson D. S., Middleton R., Sharp S. A., Smith T. J., Talcott J., Taplin M., Vogelzang N. J., Wade III J. L., Bennett C. L., Scher H. I., Initial hormonal management of Androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 Update of an American society of clinical oncology practice guideline. Journal of Clinical Oncology 2007 25 12 1596 1605 2-s2.0-35548967940 10.1200/JCO.2006.10.1949 (Pubitemid 46733088)
3. Sharifi N., Gulley J. L., Dahut W. L., Androgen deprivation therapy for prostate cancer. Journal of the American Medical Association 2005 294 2 238 244 2-s2.0-22144484150 10.1001/jama.294.2.238 (Pubitemid 41043794)
4. Alibhai S. M. H., Gogov S., Allibhai Z., Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Critical Reviews in Oncology/Hematology 2006 60 3 201 215 2-s2.0-33750729609 10.1016/j.critrevonc.2006.06.006 (Pubitemid 44709617)
5. Simon D., Preziosi P., Barrett-Connor E., Roger M., Saint-Paul M., Nahoul K., Papoz L., Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia 1992 35 2 173 177 2-s2.0-0026547429
6. Seidell J. C., Bjorntorp P., Sjostrom L., Kvist H., Sannerstedt R., Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism: Clinical and Experimental 1990 39 9 897 902 2-s2.0-0025083282 10.1016/0026-0495(90)90297-P (Pubitemid 20293933)
7. Haffner S. M., Karhapaa P., Mykkanen L., Laakso M., Insulin resistance, body fat distribution, and sex hormones in men. Diabetes 1994 43 2 212 219 2-s2.0-0028057563 (Pubitemid 24033674)
8. Haffner S. M., Mykkanen L., Valdez R. A., Katz M. S., Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. Journal of Clinical Endocrinology and Metabolism 1993 77 6 1610 1615 2-s2.0-0027131198 10.1210/jc.77.6.1610 (Pubitemid 24000922)
9. Hromadova M., Hacik T., Malatinsky E., Riecansky I., Alterations of lipid metabolism in men with hypotestosteronemia. Hormone and Metabolic Research 1991 23 8 392 394 2-s2.0-0025823446
10. Reaven G. M., Role of insulin resistance in human disease. Diabetes 1988 37 12 1595 1607 2-s2.0-0024160877 (Pubitemid 19004941)
11. Eri L. M., Urdal P., Bechensteen A. G., Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. Journal of Urology 1995 154 1 100 104 2-s2.0-0029062567 10.1016/S0022-5347(01) 67239-2
12. Smith M. R., Malkowicz S. B., Chu F., Forrest J., Sieber P., Barnette K. G., Rodriquez D., Steiner M. S., Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim Analysis of a multicenter phase III study. Journal of Clinical Oncology 2008 26 11 1824 1829 2-s2.0-42949158874 10.1200/JCO.2007.13.5517
13. Smith J. C., Bennett S., Evans L. M., Kynaston H. G., Parmar M., Mason M. D., Cockcroft J. R., Scanlon M. F., Davies J. S., The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. Journal of Clinical Endocrinology and Metabolism 2001 86 9 4261 4267 2-s2.0-0034847215 10.1210/jc.86.9.4261 (Pubitemid 32848544)
14. Dockery F., Bulpitt C. J., Agarwal S., Donaldson M., Rajkumar C., Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clinical Science 2003 104 2 195 201 2-s2.0-0037326906 10.1042/CS20020209 (Pubitemid 36238052)
15. Nishiyama T., Ishizaki F., Anraku T., Shimura H., Takahashi K., The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. Journal of Clinical Endocrinology and Metabolism 2005 90 2 657 660 2-s2.0-14044269583 10.1210/jc.2004-1611 (Pubitemid 40279176)
16. Mohamedali H. Z., Breunis H., Timilshina N., Alibhai S. M. H., Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer. Journal of the Canadian Urological Association 2011 5 1 28 32 2-s2.0-79751500103 10.5489/cuaj.09172
17. Basaria S., Muller D. C., Carducci M. A., Egan J., Dobs A. S., Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006 106 3 581 588 2-s2.0-31544440178 10.1002/cncr.21642 (Pubitemid 43157621)
18. Keating N. L., O'Malley A. J., Freedland S. J., Smith M. R., Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer. Journal of the National Cancer Institute 2010 102 1 39 46 2-s2.0-74049152290 10.1093/jnci/djp404
19. Pagliarulo V., Bracarda S., Eisenberger M. A., Mottet N., Schröder F. H., Sternberg C. N., Studer U. E., Contemporary role of androgen deprivation therapy for prostate cancer. European Urology 2012 61 1 11 25 2-s2.0-84857393219 10.1016/j.eururo.2011.08.026
20. Smith M. R., Finkelstein J. S., McGovern F. J., Zietman A. L., Fallon M. A., Schoenfeld D. A., Kantoff P. W., Changes in body composition during androgen deprivation therapy for prostate cancer. Journal of Clinical Endocrinology and Metabolism 2002 87 2 599 603 2-s2.0-0036173823 10.1210/jc.87.2.599 (Pubitemid 34158224)